
Lecanemab’s Rare and Manageable Side Effects
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
See how the class of weight loss and diabetes drugs that includes Ozempic and Wegovy have the added benefit of protecting against the development of dementia.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?
See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.
Dementia’s cholinesterase inhibitors can affect trips to the bathroom, according to researchers in Houston, Texas. Learn more if you take donepezil, rivastigmine or galantamine. (Brand names Adlarity, Aricept, Ebixa, Exelon, Namzaric, Razadyne)
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.
VIDEO + ARTICLE: Residential areas with more green space were associated with faster thinking, better attention, and higher overall cognitive function in a federal study. Learn more.
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
Alzheimer’s is characterized by an overproduction of free radicals in cells. That’s why incredibly tiny “nanoparticles” of silver, found in supplements, cosmetics and food packaging, worry scientists. Hear their concerns, as well as products to avoid.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.